Overview
![DIA Oligonucleotide-Based Therapeutics Conference](/en/-/media/americas/images/tiles/323x240/2017/17011-323x240.jpg?sc_lang=en)
On-Demand Complimentary Webinar
Oligonucleotide-Based Therapeutics in Rare Diseases
On-Demand
This webinar will examine how oligonucleotide therapeutics can be designed to modulate gene expression through multiple mechanisms and beneficially impact genetically defined rare diseases.
Access Now!
Insights Guide to Oligonucleotide-Based Therapeutics
This is a very targeted meeting and a "must attend" for those developing drugs based on oligonucleotides. It is a multidisciplinary meeting that is well organized and has several new and challenging topics where industry and regulatory agency attendees participate with a view to enabling getting drugs to patients.
-Previous Attendee
This program has been developed in collaboration with the DIA Oligonucleotide Scientific Working Group and is approved by the Regulatory Affairs Professionals Society for 12 RAC credits.
Featured
Want to learn more about DIA/FDA Oligonucleotide-Based Therapeutics Conference ? You've come to the right site!
Program Committee
-
James D. Thompson, PhD CMC Therapeutic Area Lead
Moderna Therapeutics , United States -
James Wild, PhD, MS Pharmacologist, CDER
FDA, United States -
Paul C. Brown, PhD Associate Director for Pharmacology and Toxicology, OND, CDER
FDA, United States -
Daniel Capaldi, PhD Vice President, Analytical and Process Development
Ionis Pharmaceuticals, Inc, United States -
Xuan Chi, PhD Supervisory Pharmacologist
CDER, FDA, United States -
Robert T. Dorsam, PhD Associate Director, Pharmacology/Toxicology, Office of Generic Drugs, CDER
FDA, United States -
Scott Henry, PhD Senior Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States -
Aimee L. Jackson, PhD Chief Scientific Officer
Atalanta Therapeutics, United States
Have an account?